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Copyright © 200? JCBN Summary The present study was conducted to investigate the prevalence of mucosal injury
in patients taking low-dose aspirin in Japan and examine the effect of gastric mucoprotective
drugs on aspirin-related gastroduodenal toxicity. We selected 530 patients who had taken low-
dose aspirin for 1 month or more after undergoing esophagogastroduodenoscopy from 2005
through 2006 at Teikyo University Hospital, Tokyo, Japan. Endoscopic records were retrospec-
tively reviewed to determine the presence of massive bleeding and mucosal injury (ulcer or
erosion). The influence of clinical factors, including co-administration of gastroprotective
drugs, was also examined. Hemorrhage was observed in 25 patients (3.7%) and mucosal injury
(36.2%) in 192 patients. The presence of Helicobacter pylori antibody was a significant risk
factor associated with mucosal injury. Patients taking any gastroprotective drug showed a
significantly lower rate of mucosal injury than those not taking these drugs. Patients taking
rebamipide concomitantly with proton pump inhibitors or histamine 2 receptor antagonists
had mucosal injury less frequently than those taking acid suppressants plus other muco-
protective drugs. In conclusion, these results show the possible gastroprotective effects of
rebamipide, suggesting that it may be a good choice in aspirin users with gastroduodenal
toxicity that is not suppressed by acid suppressants alone.
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Introduction
Gastrointestinal toxicity induced by non-steroidal anti-
inflammatory drugs (NSAIDs) is one of the major causes of
peptic ulcers. Due to its widespread use, low-dose aspirin
(LDA), which is used for prophylaxis of atherothrombotic
diseases, plays an important role in the occurrence of peptic
ulcers. In Japan, administration of LDA has been rapidly
increasing as the population ages.
Previous studies have shown that upper gastrointestinal
bleeding caused by LDA can be decreased with acid sup-
pressants, such as proton pump inhibitors (PPI). Unfortu-
nately, these protective effects are incomplete, and new
therapeutic options have not been developed [1–4]. Many
gastroduodenal mucoprotective drugs have not been evaluated
in terms of efficacy for LDA-related toxicity, although they
are often used in clinical settings in Japan. In addition, there
is little clinical information and the current condition of
LDA-related gastrointestinal mucosal injury remains uncer-
tain in Japanese subjects [5, 6]. We conducted this study to
clarify the current condition of mucosal injury in JapaneseT. Yamamoto et al.
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patients taking LDA and to identify potential effective treat-
ments against LDA-induced mucosal injury.
Materials and Methods
This study involved a retrospective review of medical
records. From January 2005 through December 2006, 5555
patients underwent upper gastrointestinal endoscopy at the
Department of Internal Medicine of Teikyo University
Hospital (Tokyo, Japan). Among these patients, 548 had
taken LDA for 1 month or more and were selected for
inclusion in this study. Patients with malignant diseases,
hemorrhage from variceal lesions, and Mallory-Weiss
syndrome were excluded because of difficulty in performing
accurate endoscopic evaluations. Thus, 530 patients were
enrolled as study subjects. All endoscopic examinations
performed at this hospital are recorded with more than 20
photographs. Two well-trained examiners with more than 10
years’ experience retrospectively evaluated endoscopic
records to determine whether gastroduodenal mucosal injury
and bleeding from the lesion were present; examiners were
blinded to patient data. If the two examiners differed in
opinion, another examiner evaluated the record again to
make a final diagnosis. Bleeding was diagnosed on the basis
of endoscopic evidence of current or recent hemorrhage
with drop of hemoglobin of 2 g/dl or more, which was
judged to require hospitalization. Minor hemorrhages
judged to be treatable on an outpatient basis, such as small
clots attached to the gastric wall, were not classified as
“bleeding” in the present study. Mucosal injury was defined
as obvious findings of gastroduodenal mucosal defects
including both erosion (less than 5 mm in diameter) and
ulcer (more than 5 mm).
Background characteristics of the subjects (age, gender,
underlying disease, reason for undergoing examination, past
history of gastroduodenal ulcer, and concomitant admin-
istration of warfarin, NSAIDs, PPI, histamine 2-receptor
antagonists (H2RA), or other gastric mucoprotective (MP)
agents) were ascertained from medical records. The pres-
ence of serum anti-Helicobacter pylori (H. pylori) antibody
was tested using a commercially available kit (E-plate®,
Eiken Chemical Co., Tokyo, Japan) in participants who gave
written informed consent. Chart review was performed to
confirm the present status of the infection in subjects that
underwent past eradication treatment.
Unadjusted odds ratios (OR) and 95% confidence intervals
(CI) were calculated to clarify the significance of differences
between two groups, if appropriate. Prior to the study, the
protocol was approved by the institutional review board of
Teikyo University.
Results
Underlying diseases of subjects included ischemic heart
disease (66%), cerebrovascular disease (30%), and systemic
arteriosclerosis (8%). The influence of background charac-
teristics on gastroduodenal bleeding and mucosal injury
are shown in Tables 1 and 2. The only factor significantly
associated with reduced bleeding was co-administration of
a PPI. In terms of mucosal injury, use of a PPI decreased
the prevalence of mucosal injury, whereas the presence of
H. pylori increased the prevalence (Table 2). The impact of
gastric protective medications on gastroduodenal toxicity is
presented in Table 3. Compared to patients not receiving any
gastroprotective medication, any treatment was associated
with significantly lower rates of bleeding and mucosal injury
Table 1. Effect of baseline characteristics on gastroduodenal bleeding in patients taking low-dose aspirin
p values were calculated with chi-square test or t test. Abbreviations: H. pylori, serum anti-Helicobacter pylori antibody; PPI, proton
pump inhibitor; NSAIDs, nonsteroidal anti-inflammatory drugs; AP, anti-platelet agents; AC, anticoagulants.
Baseline characteristics Bleeding+ (n = 25) Bleeding– (n = 505) Odds ratio (95% CI) p value
Age (years) 70.3 ± 11.6 69.5 ± 11.3 ns
Male 14 281 1.01 ns
Female 11 224 (0.73–3.27)
H. pylori+ 17 158 1.86 ns
H. pylori– 6 104 (0.71–4.88)
PPI+ 5 211 0.34 <0.05
PPI– 20 294 (0.12–0.94)
History+ 7 122 1.22 ns
History– 18 383 (0.49–2.99)
NSAIDs+ 1 23 0.87 ns
NSAIDs– 24 482 (0.11–6.74)
AP or AC+ 4 99 0.54 ns
AP or AC– 21 406 (0.09–2.10)Aspirin-Related Mucosal Injury and Rebamipide
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(p<0.01 for both comparisons). Similarly, use of a PPI
alone was significantly more protective against bleeding
and mucosal injury than non-use of any medicine (p<0.01
for both comparisons). In terms of combination therapy,
patients taking a PPI or H2RA plus an MP agent showed
significantly better outcomes in terms of mucosal injury
compared to patients taking no medication. Use of a PPI/
H2RA plus rebamipide was associated with a better overall
outcome (bleeding, mucosal injury) than acid suppressants
plus other MPs, although the rate of H. pylori infection, a
significant confounding factor, did not differ between two
groups (Table 4).
Discussion
Aspirin, even in low doses, induces gastrointestinal
mucosal injury and hemorrhage, which limits its clinical
use. LDA-induced gastrointestinal toxicity has become a big
problem in Japan as well as other countries. A case-control
study of hemorrhagic peptic ulcer patients indicated that the
risk of LDA for bleeding from ulcers is similar to other
NSAIDs [7]. Other reports also support the high prevalence
of gastroduodenal mucosal injury in LDA users [5,  6].
Although information is limited in Japanese patients, data
indicate that effective treatments are needed for LDA-
Table 2. Effect of baseline characteristics on gastroduodenal mucosal injury in patients taking low-dose aspirin
p values were calculated with chi-square test or t test. Abbreviations: H. pylori, serum anti-Helicobacter pylori antibody; PPI, proton
pump inhibitor; NSAIDs, nonsteroidal anti-inflammatory drugs; AP, anti-platelet agents; AC, anticoagulants.
Baseline characteristics Mucosal injury+ (n = 192) Mucosal injury– (n = 338) Odds ratio (95% CI) p value
Age (years) 69.2 ± 10.7 69.8 ± 11.6 ns
Male 113 182 1.2 ns
Female 79 156 (0.84–1.72)
H. pylori+9 3 8 2 2 . 1 4 < 0 . 0 1
H. pylori– 38 72 (1.31–3.51)
PPI+ 51 165 0.38 <0.01
PPI– 141 173 (0.26–0.57)
History+ 53 76 1.3 ns
History– 139 262 (0.86–1.95)
NSAIDs+ 8 16 0.86 ns
NSAIDs– 184 322 (0.36–2.06)
AP or AC+ 48 85 0.99 ns
AP or AC– 144 253 (0.65–1.49)
Table 3. Impact of gastroprotective medications on endoscopic findings
#sucralfate, aldioxa, cetraxate, sofalcone, and sodium alginate, all which were prescribed for less than 10 patients. *p<0.05,
**p<0.01, compared with no-medication group (chi-square test). Abbreviations: PPI; proton pump inhibitor, H2RA; H2
receptor antagonist, MP; mucoprotective agent.
Treatment Number Bleeding Mucosal injury H. pylori
None 118 11 (9.3%) 58 (49.1%) 46/73 (63.0%)
Any medicine 412 14 (3.4%)** 134 (32.5%)** 129/222 (58.1%)
PPI 145 3 (2.1%)** 27 (18.6%)** 39/71 (54.9%)
H2RA 82 4 (4.9%) 33 (40.2%) 25/45 (55.6%)
MP 74 2 (2.6%) 38 (51.4%) 31/42 (73.8%)
PPI/H2RA + MP 111 5 (5.4%) 36 (32.4%)* 34/59 (57.6%)
Teprenone 33 2 (6%) 14 (42.4%) 12/20 (60.0%)
Rebamipide 27 0 (0%) 4 (14.8%) 7/13 (53.8%)
Ecabet sodium 14 2 (14.2%) 4 (28.6%) 2/8 (25.0%)
Polaprezinc 13 0 (0%) 4 (30.8%) 6/12 (50.0%)
Others# 26 1 (3.8%) 10 (38.5%) 7/11 (63.6%)
Total 530 25 (4.7%) 192 (36.0%) 175/295 (59.3%)T. Yamamoto et al.
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related gastrointestinal toxicity in Japanese patients as well.
Previous studies support the avoidance of LDA when
risks outweigh benefits [8]. However, in cases in which
LDA use is required, such as after placement of a drug-
eluted coronary stent, protection of gastrointestinal mucosa
against LDA-injury is important. Proven treatment for LDA-
related mucosal injury includes co-administration of a PPI
and eradication of H. pylori. Because these treatments are
comparable in efficacy, but do not provide complete protec-
tion, other therapeutic options are needed. Co-administration
of acid suppressants and other gastroprotective medicines is
one possible treatment, although we can find only one report
regarding this treatment [9].
The present data clearly showed the effectiveness of acid
suppressants, especially PPI, for suppressing LDA-induced
mucosal damage, which is consistent with previous data [6].
Patients receiving any gastroprotective medicine suffered
from mucosal injury significantly less frequently than those
who did not receive any medication. In addition, acid
suppressants plus rebamipide showed a trend of lowering
gastroduodenal damage. This additive effect was not seen
with other mucoprotective agents. Rebamipide provides it
gastric mucoprotective effect via different mechanisms from
acid suppressants, which affect not only the upper gastro-
intestinal tract but also other intestinal organs [10–15].
Rebamipide stimulates the production of prostaglandins and
epidermal growth factor, preventing H. pylori-elicited
neutrophil-induced mucosal injury and decreasing free
radical levels [16,  17]. Clinically, the efficacy against
NSAID-induced gastric injury is reported as comparable to
that of low-dose famotidine, one of H2RA [18]. The present
results suggest the new potential for use of rebamipide with
a PPI and H2RA to protect against LDA-related intestinal
damage.
The limitations of the present study include the retrospec-
tive study design, the small sample number, and the fact
that all patients were drawn from a single institute. Because
selection bias may have affected the present results, data
should be interpreted carefully. A prospective trial is needed
to clarify the effect of rebamipide added to PPIs and H2RA
therapy on the prevention of aspirin-induced GI injury.
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